Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02DEH
|
|||
| Former ID |
DIB001820
|
|||
| Drug Name |
GM-602
|
|||
| Synonyms |
Alirinetide; UNII-6BK9OEG8CC; 6BK9OEG8CC; 725715-18-4; GM-603; GM-605; GM-604; GM-607; GM-609; GM-606; L-Arginine, L-phenylalanyl-L-seryl-L-arginyl-L-tyrosyl-L-alanyl-; (2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-(((2S)-2-Amino-3-phenyl-propanoyl)amino)-3-hydroxy-propanoyl)amino)-5-guanidino-pentanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)propanoyl)amino)-5-guanidino-pentanoic acid
Click to Show/Hide
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Amyotrophic lateral sclerosis [ICD-11: 8B60.0] | Phase 2 | [2] | ||
| Ischemic stroke [ICD-11: 8B11.5Z; ICD-9: 434.91] | Phase 2 | [2] | ||
| Company |
Genervon biopharmaceuticals
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C36H54N12O9
|
|||
| Canonical SMILES |
CC(C(=O)NC(CCCN=C(N)N)C(=O)O)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CCCN=C(N)N)NC(=O)C(CO)NC(=O)C(CC2=CC=CC=C2)N
|
|||
| InChI |
1S/C36H54N12O9/c1-20(29(51)46-26(34(56)57)10-6-16-43-36(40)41)44-32(54)27(18-22-11-13-23(50)14-12-22)47-31(53)25(9-5-15-42-35(38)39)45-33(55)28(19-49)48-30(52)24(37)17-21-7-3-2-4-8-21/h2-4,7-8,11-14,20,24-28,49-50H,5-6,9-10,15-19,37H2,1H3,(H,44,54)(H,45,55)(H,46,51)(H,47,53)(H,48,52)(H,56,57)(H4,38,39,42)(H4,40,41,43)/t20-,24-,25-,26-,27-,28-/m0/s1
|
|||
| InChIKey |
WVPOPWDCSFQEBI-HJJAOGADSA-N
|
|||
| CAS Number |
CAS 725715-18-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01221246) Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.